Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × sabatolimab × 1 year × Clear all
NCT04150029 2026-01-13

STIMULUS-AML1

Novartis

Phase 2 Terminated
90 enrolled 26 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Novartis

Phase 3 Terminated
530 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Novartis

Phase 1/2 Terminated
24 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡